DevalingamMahalingamMD

Oncology • Chicago, IL

Assistant Professor, Medicine, University of Texas Medical School, San Antonio

Join to view full profile

Dr. Mahalingam is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mahalingam's full profile

Already have an account?

Office
645 N Michigan Ave
Ste 1006
Chicago, IL 60611
Phone+1 210-413-1723

Fax+1 210-450-1150

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 2008 - 2009
National University of Ireland, Galway Faculty of MedicineClass of 2000

Certifications & Licensure

IL State Medical License 2017 - 2026
TX State Medical License 2011 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma Start of enrollment: 2009 Sep 01
Completed
Phase 2
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma Start of enrollment: 2009 Oct 01
Completed
Phase 2
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors Start of enrollment: 2009 Nov 01
Completed
Phase 1
Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors Start of enrollment: 2010 Jan 01
Completed
Phase 1
Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma Start of enrollment: 2013 Apr 01
Completed
Phase 1, Phase 2
A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer Start of enrollment: 2012 Sep 01
Completed
Phase 1, Phase 2
Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer Start of enrollment: 2011 Apr 01
Completed
Phase 2
Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma Start of enrollment: 2013 Jan 01
Completed
Phase 2
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm Start of enrollment: 2013 Jul 01
Completed
Phase 1
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab Start of enrollment: 2014 May 05
Completed
Phase 1
Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma
No longer available
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer Start of enrollment: 2017 Feb 16
ACTIVE_NOT_RECRUITING
PHASE2
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 Start of enrollment: 2019 Jan 29
ACTIVE_NOT_RECRUITING
PHASE2
Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer Start of enrollment: 2018 Nov 14
Terminated
Phase 2
9-ING-41 in Patients with Advanced Cancers Start of enrollment: 2019 Jan 04
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Start of enrollment: 2023 Mar 08
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma.
Tarik Demir, Carolyn Moloney, Devalingam Mahalingam
Cancers. 2025-02-20
Delta Radiomics and Tumor Size: A New Predictive Radiomics Model for Chemotherapy Response in Liver Metastases from Breast and Colorectal Cancer.
Nicolò Gennaro, Moataz Soliman, Amir A Borhani, Linda Kelahan, Hatice Savas
Tomography. 2025-02-20
A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers.
Devalingam Mahalingam, Taofeek K Owonikoko, Ebrahim Delpassand, Mary F Mulcahy, Aparna Kalyan
Cancer. 2025-01-01

Grant Support

North American Star ConsortiumUNIVERSITY HEALTH NETWORK2014–2026

Other Languages

Malay